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Abstract: BACKGROUND AIMS An optimal allocation system for scarce resources should simulta-
neously ensure maximal utility, but also equity. The most frequent principles for allocation policies in
liver transplantation are therefore criteria that rely on pre-transplant survival (sickest first policy), post-
transplant survival (utility), or on their combination (benefit). However, large differences exist between
centers and countries for ethical and legislative reasons. The aim of this study was to report the current
worldwide practice of liver graft allocation and discuss respective advantages and disadvantages. METH-
ODS Countries around the world that perform 95 or more deceased donor liver transplantations per year
were analyzed for donation and allocation policies, as well as recipient characteristics. RESULTS Most
countries use the model for end-stage liver disease (MELD) score, or variations of it, for organ allocation,
while some countries opt for center-based allocation systems based on their specific requirements, and
some countries combine both a MELD and center-based approach. Both the MELD and center-specific
allocation systems have inherent limitations. For example, most countries or allocation systems address
the limitations of the MELD system by adding extra points to recipient’s laboratory scores based on
clinical information. It is also clear from this study that cancer, as an indication for liver transplantation,
requires special attention. CONCLUSION The sickest first policy is the most reasonable basis for the
allocation of liver grafts. While MELD is currently the standard for this model, many adjustments were
implemented in most countries. A future globally applicable strategy should combine donor and recipient
factors, predicting probability of death on the waiting list, post-transplant survival and morbidity, and
perhaps costs. LAY SUMMARY An optimal allocation system for scarce resources should simultaneously
ensure maximal utility, but also equity. While the model for end-stage liver disease is currently the stan-
dard for this model, many adjustments were implemented in most countries. A future globally applicable
strategy should combine donor and recipient factors predicting probability of death on the waiting list,
post-transplant survival and morbidity, and perhaps costs.
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Background: An optimal allocation system for scarce resources should 
simultaneously ensure maximal utility, but also equity. The most frequent principles 
for allocation policies in liver transplantation (LT) are therefore criteria that rely on 
pre-transplant survival (sickest first policy), post-transplant survival (utility), or on their 
combination (benefit). Large differences however exist between centers and 
countries for ethical and legislative reasons. 
Aim: To report the current worldwide practice of liver graft allocation and discuss 
respective advantages and disadvantages. 
Methods: Countries around the world performing ≥ 95 or more deceased donor liver 
transplantations per year were analyzed for donation and allocation policies, as well 
as recipient characteristics. 
Results/Conclusion: The sickest first policy is the most appropriate basis for the 
allocation of liver grafts. While MELD is currently the standard for this model, many 
adjustments were implemented in most countries. A future globally applicable 
strategy should combine donor and recipient factors predicting probability of death on 






Liver transplantation (LT) has been undoubtedly one of the most successful 
procedures developed in the late 20th century, and as a consequence allocation of 
scarce liver grafts has caused many controversies (Fig. 1-2) [1]. In the early stages of 
the procedure, from 1980s until mid-1990s, liver grafts were prioritized in the USA 
based on the degree of sickness and localization of the patients in the hospital [2]. 
For example, candidates admitted to an intensive care unit (ICU) received the highest 
priority taking over on patients hospitalized in a non-ICU setting as well as 
outpatients, somewhat independently of their accumulated waiting time [3]. This 
policy carried the obvious risk of spoiling the system by forcing competing centers to 
keep the candidates on the ICU in order to get priority, when an organ became 
available. Next to the location of the patients, listing time was an important variable; 
patients listed early in a compensated stage of liver disease could gain much priority 
[4]. As a consequence, a minimal listing criterion was introduced based on the Child–
Turcotte–Pugh (CTP)-score with a minimum of 7 out of 15 points to qualify for listing 
[5]. The introduction of this additional criterion, however, did not reduce the number 
of listed candidates because waiting time remained the most important recipient 
variable for organ allocation, until Freeman et al. reported a lack of correlation 
between waiting time and waiting list mortality [6]. This has led to a change in 
paradigm as waiting time was no longer a key criterion for organ allocation [7].  
Subsequently, the social and political requests for a better allocation system 
focusing on patient’s medical condition and some notion of justice led to the 
implementation of the currently widely used allocation policy based on the model for 
end-stage liver disease (MELD score) [8]. The MELD score is composed of three 





the international normalized ratio (INR) of prothrombin time), which was originally 
designed as a predictive tool for survival of patients receiving a transjugular 
intrahepatic portosystemic shunt (TIPS)  (supp. Fig. 1) [9, 10]. The model was 
subsequently validated in a large cohort of patients suffering from chronic liver 
disease for the prediction of the 3-month mortality irrespective of the etiology of liver 
disease or presence of portal hypertension [11]. 
Since 2002, the MELD score has been adopted by the United Network for 
Organ Sharing (UNOS) in the USA, followed by North Italian transplant (2006), 
Eurotransplant (2006), Canada (2004-2006), France (2007), Switzerland (2007) and 
other countries with a high number of transplantations such as China and Brazil (Tbl. 
1; Fig. 1-2; supp. Fig 1.) [12, 13]. The MELD-based allocation is consecutively 
performed by most countries worldwide performing more than 95 LT per year (sup. 
Tbl. 1) [14]. In contrast, a center specific allocation policy remains popular in other 
parts of the world, especially in areas with high donation rates, such as Portugal and 
Scandinavia. As a putative advantage, this policy offers transplant centers the degree 
of freedom to allocate and match the graft to the presumed optimal recipient. 
Moreover, some countries like Spain and Canada combine the MELD and the center-
specific allocation policy with remarkable outcome results [15]. The UK introduced a 
new allocation scheme in 2018 based on survival benefit. Priority is given to urgent 
cases and to those patients on the list with the highest Transplant Benefit Score 
(TBS), based on the best match of 7 donor and 21 recipient parameters (Tbl. 1; sup. 
Tbl. 1-2; supp. Fig. 1) [16].  
An alternative to these allocations models are scores to define a threshold for 
declining livers to avoid unfavorable risk accumulation in high MELD patients (BAR, 





scoring system to predict outcome after orthotopic liver transplantation with respect to 
recipient, donor and graft factors. It was calculated on 37.255 patients in the UNOS 
(United Network for Organ Sharing) database and identifies the six strongest 
predictors of post transplantation patient survival. Analysis confirmed the superiority 
of BAR as compared to other score systems like MELD, D-MELD, DRI and SOFT. 
The score was validated using the ELTR database. The BAR compared to other 
scores offers a well-defined cut off for decision making. 
The recent extension of transplant indications, for example for malignancy 
including cholangiocarcinoma, HCC, and colorectal liver metastases, has further 
aggravated organ shortage and led again to a competition in the allocation for liver 
grafts (Tbl. 2; supp. Tbl. 2; Fig. 3; supp. Fig. 1) [4, 17, 20-23].  
While benchmarking for LT has been implemented in a recent study to define 
the optimal achievable results in “ideal” candidates [24], it remains however unclear, 
how non ideal candidates and marginal grafts should be best allocated in face of the 
huge differences in local legislative regulations, education as well as public attitudes, 
culture and religion. We report in the following on current distribution systems for liver 
grafts worldwide (Fig. 1.). 
 
Materials and methods:  
To collect data transplant centers from countries around the world performing 
95 or more deceased donor liver transplantations per year were contacted (Fig. 1. – 
2). A total of 2 email reminders were sent within a period of 4 weeks. All countries 






Allocation Systems of Liver Grafts Worldwide 
1. Europe 
In 2013 more than 7000 liver transplantations, a third of LT worldwide, were 
performed in Europe (ELTR) [25]. In fact, there is a trend to further increasing LT, 
mostly due to the increase in donor rates by 25% in several European countries in 
the past few years [25]. One of the most important findings in the evolution of LT is 
the significant improvement of results over time, leading to a current 1- and 5-year 
survival rate of 96% and 82%, respectively (sup. Tbl. 1). Notably, the LT rate in the 
EU countries vary widely from 8 to more 26 persons per million population (pmp) 
(Fig. 2). These differences encompass legislation, indications for LT, investments in 





Donation policy:   Opt in (DE, NL), Opt out (all others) 
Prioritization:    Clinical & MELD 
Priority for HCC:  Yes. The Netherlands 10% MELD equivalent, other countries 15%  
MELD equivalent; additional points: after 90d days 10% MELD 
equivalent. 
Indications for extra points: Neoplasia, Biliary atresia, PLD, PSC, Haemangioendothelioma, HHT, 







Eurotransplant is a non-profit organization founded in 1967 covering the 
international organ-exchange among Austria, Belgium, Croatia, Germany, Hungary, 
Luxembourg, the Netherlands and Slovenia. While each country in the 
Eurotransplant program follows its own legislation, including the use of donors after 
cardiac death (DCD) or prioritization on the waiting list, Eurotransplant has a supra-
national mediating role on graft allocation, aiming to prevent graft loss and to achieve 
a better donor-recipient match. The Eurotransplant region has a population of 
approx.136 million people. This large donor and recipient pool allows matching 
between the available donor organs and the patients on the waiting list. Special 
patient groups like children, high urgent patients or highly immunized patients have 
therefore a chance of receiving a suitable donor organ in time.  A payback rule 
regulates that a specific country is obliged to offer back a liver – the next available 
liver with the same bloodgroup - if they have received a liver for a high urgency 
(ACO) recipient from another Eurotransplant country.  
With regard to donation rates, there is a high variability across the 
Eurotransplant area, ranging from 5.3 pmp in Luxembourg to 37.6 pmp in Croatia. 
The median deceased donor rate is 14.2 pmp, with an increasing donor age over the 
past years (current median of 54 years), as the number of octogenarian donors 
doubled in the last decade. The graft utilization rate is 74% [26]. 
In the Eurotransplant area, more than 1500 LTs are performed each year in 38 
centers. The treaties aim to balance the number of LT considering the high 
heterogeneity among different countries. LT candidates are listed according to three 
different prioritization categories: high urgency, combined transplantation with other 
organs and elective liver transplantation, which accounts for approximately 86% of LT 
recipients. The main strength caused by the resulting wide donor pool is that patients 





liver failure, may benefit from a very short waiting time with a median of 2 days. The 
use of an urgent graft from another country should, however, be compensated by a 
"payback" graft [27].  
LT candidates listed in the elective groups are managed according to national 
allocation policies. In Germany and the Netherlands, a recipient-driven model 
determines graft allocation to the sickest patient, regardless of the center. However, 
in case of donors with hemodynamic instability or technical difficulties, a non-
standard allocation model ("extended" or "rescue" allocation systems, accounting for 
20-25% LT performed each year) can be used to prevent graft deterioration or loss. 
In the Eurotransplant program, the MELD score is capped at 40 points, and extra-
points are granted to patients with well-defined exceptions such as biliary atresia, 
primary hyperoxaluria, urea cycle disorder, haemangioendotheloima and others (Tbl. 
1-2; supp. Tbl. 1-2; Fig. 1–3 and supp. Fig. 1) [27]. 
 
1.2. Scandiatransplant  
 
Donation policy:   Opt-out 
Prioritization:    Clinical, waiting time 
Priority for HCC:   No 
Indications for extra points:  Not applicable 
 
In contrast to middle Europe, Nordic European countries are characterized by 
significant societal and cultural differences reflecting on the prevalence of liver 
donations and, subsequently LT. According to the Nordic Liver Transplant Registry 
(NLTR), primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC) 





cirrhosis represent less than 10%. The number of candidates active on the waiting list 
(110 patients), the waiting time to get a graft and consequently mortality on the 
waiting list (about 6%) are lower than in any other area around the globe. Given that 
the MELD score predicts 3-month survival for patients with cirrhosis, it is clearly not a 
useful tool to assess prioritization in a population with such underlying characteristics. 
Therefore, Scandinavian countries have kept a center-driven allocation policy.  
According to the NLTR, which is managed by Scandiatransplant, > 5000 LT 
have been performed since the first LT performed in Helsinki in 1982. Supply of 
grafts is high with donation rates ranging from 15.3 pmp in Denmark to 40 pmp in 
Iceland [28, 29]. With regard to donor age, Scandiatransplant present data similar to 
other European countries, with a median donor age of 54 years, and a homogeneous 
increase in the utilization of organs from septuagenarian and octogenarian donors. 
One and 5-year post-LT survival is 92% and 81%, respectively [28]. 
 
The high organ availability in Scandinavian countries has led to a broadening of 
indications in LT. For example, a modest expansion of Milan criteria for HCC, which 
represents only 9% of indications has been adopted according to the Oslo Criteria in 
2005 in Norway [28, 30]. Median time on the waiting list for HCC patients is short, 
probably because of the good balance between the HCC burden on the waiting list 
and the center-driven allocation policy. Post-LT survival for HCC (1 and 5-year 85% 
and 57%) is lower than for non-HCC recipients, which is comparable with data from 
different allocation systems [31].  
 
In addition to expanding the criteria for HCC, the group from Oslo investigated 





resectable colorectal liver metastases. After a median follow-up time of 27 months, 
the 1- and 5-year estimated post-LT overall survival were 95% and 60%, 
respectively, and a 35% 1-year disease free survival. Although the authors 
demonstrated a survival comparable to re-LT patients, data have to be clearly 
confirmed with larger studies and several ethical and cultural concerns have to be 
faced before considering non-resectable liver metastases as a stable indication for 
LT (Tbl. 1-2; supp. Tbl. 1-2; Fig. 1–3 and supp. Fig. 1) [32, 33]. 
 
1.3. France  
 
Donation policy:   Opt-out 
Prioritization:    Clinical, French Liver Score 
Priority for HCC:  Only for recurrent HCC, extra points granted (Recurrence of a treated 
single HCC within AFP-score) 
Indications for extra points:  Recurrent HCC, PLD, HHT, Amyloidosis, Metabolic disease, Recurrent 
cholangitis, HPS, Ascites 
 
The National transplant program in France is managed by the “Agence de la 
Biomédecine”, founded in 2004. The LT program has grown over the past decade 
with the usage of DCD organs after a specific legislation passed in 2010, and the 
establishment of organ donation as a national priority. HCC has become the lead 
indication in 2014, followed by alcohol-related cirrhosis (30% and 28% of the 
indications, respectively) [34]. 
The allocation rules for DBD have been modified in France in 2007, up to this 
time allocation followed a center-driven policy with the exception of emergency 





mortality ranging from 3% to 24% depending on the region. A new allocation system, 
the French Liver Allocation Score (FLAS), is currently in place affecting nearly 80% of 
liver grafts in 2015 [15]. This score reflects severity of cirrhosis according to MELD 
score, but attributes also a defined number of points for the accumulation waiting 
time. The French allocation system allows to include patients with HCC outside the 
Milan criteria as well as those undergoing surgical resection before disease 
recurrence [30]. In addition, the Liver Transplantation French Study Group has shown 
that the prediction of tumor recurrence is improved significantly by a model that 
incorporates α fetoprotein (αFP) [35]. With regard to the DCD program, only 5 
centers have been authorized to perform organ procurement to date (Tbl. 1-2; supp. 
Tbl. 1-2; Fig. 1–3 and supp. Fig. 1).    
 
1.4. Italy  
 
Donation policy:   Opt-out 
Prioritization:    Clinical, MELD 
Priority for HCC:   Yes, extra points granted at listing 
Indications for extra points:  HCC, Complications of PH 
 
The Italian organ transplantation network is governed by the National 
Transplantation Center (CNT) with more than 1000 LT since 2014, half of which have 
been performed in 6 centers in Northern Italy. There are 21 LT centers in 13 regions, 
grouped into 2 macro areas (central-Northern and central-Southern Italy). 
Interregional institutions (e.g. the North Italian Transplant programs) have a 
mediating role among centers granting graft rotations respecting a pay-back system, 





organ donation between Northern and Southern regions (mean donation rate in Italy 
22.6 pmp in 2015, ranging from 9.8 pmp in Sicily to 48 pmp in the region of Tuscany) 
[36].  
Organs are shared nationwide for the most severely ill candidates in a super-
urgent setting, by macro-area for patients with MELD ≥ 30 and regionally for patients 
with MELD < 30. A large cohort of Italian LT recipients (n= 2061) were recently 
compared with a matched English cohort (n=2121) showing that strategies to drive 
allocation are lacking in both cohorts, except for split-livers (mainly allocated to non-
HCV recipients) and HCC patients who received grafts from older donors [37]. Thus, 
a recent consensus conference was held to identify new allocation policies respecting 
criteria for MELD exceptions [38]. A DCD program has been started in Milan 
Niguarda Hospital since 2015 with 28 liver transplantations performed so far (Tbl. 1-
2; supp. Tbl. 1-2; Fig. 1–3 and supp. Fig. 1) [39].    
 
1.5. Spain  
 
Donation policy:   Opt-out 
Prioritization:    Clinical, MELD 
Priority for HCC:   Yes, extra points granted 
Indications for extra points:  HCC (region-specific) 
 
Liver transplantation started in Spain in 1984, currently involving 24 centers, five 
of which include a pediatric LT program. More than 1000 LT/year are performed in 
Spain, which translates in the highest European transplant rate (25 pmp) and one of 
the highest European organ donation rates (39.7 pmp), with an increasing trend over 





donors to be referred to appropriate ICUs. The plan encourages the use of extended 
donor criteria organs including DCD [41]. The DCD program expanded much since 
2014 with the use of controlled DCDs making Spain the third country for the use of 
DCD organs after the US and UK [42]. 
The country is subdivided in several regions each with its own particularity 
regarding the organ allocation process. The National Spanish Organization (ONT) 
manages organ allocation through a center-oriented strategy, even if nationwide 
allocation is granted for super-urgent cases. The center-driven allocation policy 
allows for a clinician-guided decision independent of the degree of sickness of the 
potential candidates, as the final decision regarding donor-recipient matching is 
made internally by the local team. In contrast to other countries with a center-driven 
allocation policy, the Spanish centers also utilize the MELD system to guide patient 




Donation policy:   Opt-in 
Prioritization:    Clinical, MELD, waiting time 
Priority for HCC:  Yes, extra points granted (at listing: 14; additional 1.5 points/month) 
Indications for extra points:  Neoplasia, Amyloidosis, Primary Hyperoxaluria, HRS, PPH 
 
The Swisstransplant foundation manages organ allocation throughout the 
country. Organ donation rates remained low at 14.1 pmp. Only three liver transplant 
centers are active to cover about 100 -120 liver transplants per year. MELD allocation 





receiving 1.5 points per month, starting at MELD 14. Non-standard exceptions are 
granted by a national audit group, if needed. Based on poor donations rates to cover 
many high-risk candidates, the balance of risk (BAR) score was developed in 2011, 
which sums up six key donor and recipient risk factors (donor age, cold ischemia, 
recipient age, retransplantation, ventilator dependency, MELD score) for reliable 
prediction of patient survival [18]. This score has been validated in the UNOS and 
ELTR databases. A DCD liver transplant program has been started in 2012 in Zurich 
with the use of a newly designed machine perfusion technique, hypothermic 
oxygenated perfusion (HOPE), which is applied end-ischemic directly before 
implantation [44]. Since 2018 both other programs are also using DCD grafts (Tbl. 1-
2; supp. Tbl. 1-2; Fig. 1–3 and supp. Fig. 1). 
  
1.7. United Kingdom 
 
Donation policy:   Opt-in 
Prioritization:    TBS, UKELD 
Priority for HCC:   No 
Indications for extra points:  Recurrent cholangitis, Metabolic disease, HPS 
 
The UK LT program is the oldest one in Europe, since the first LT was 
performed in Cambridge in 1968 [45]. This program accounts for about 850 LT per 
year covering only 7 centers (one in Scotland and six in England) [46]. There has 
been an increasing number of donations (20.3 pmp in 2015) and LT's over the past 5 
years (+26% from 2011 to 2015), mostly as a consequence of an operative Task 





the second country in terms of the frequency of DCD organ utilization after the US, 
which contributes to more than 20% of the donor pool [47]. The donation process is, 
however, accompanied by a high discard rate (national offer decline rate is 15% for 
both donors after brain and cardiac deaths), due to a high donor age and predicted 
high-risk transplantation.  
The assessment of waiting list prioritization in the UK was established by 
UKELD, which was developed after a nationwide evaluation of the English LT 
scenario [48]. All non-HCC patients listed for LT in the 7 LT centers across the UK 
from 2003 to 2006 were evaluated, identifying a specific score (comprising sodium, 
creatinine, INR and bilirubin), that performed better than MELD score in predicting 
survival. The allocation system has been center-driven until 2018, with designated 
zones periodically revised and rebalanced among centers, although a prioritization 
for super-urgent patients (ALF, or early graft failure) is nationally assured. The UK 
introduced in 2018 a new allocation scheme. Priority is still given to those patients on 
the ‘super urgent’ list. However, if there is no patient on the super urgent list, the 
available liver is then offered to patients on the list with the highest Transplant Benefit 
Score (TBS) taking into account 7 characteristics from the donor and matching those 
with 21 recipient characteristics (Tbl. 1-2; supp. Tbl. 1-2; Fig. 1–3 and supp. Fig. 1) 
[16].   
 
2.  North America 
 
2.1  USA 
 
Donation policy:   Opt-in 





Priority for HCC:  None at listing. Median MELD at transplant at surrounding centers less 
3 MELD points starting 6 months after listing. 
Indications for extra points:  Neoplasia, Cystic Fibrosis, FAP, Primary Hyperoxaluria, Metabolic 
Disease, HPS, PPH 
 
Organ allocation is managed in the US by a private non-profit organization, the 
united network for organ sharing (UNOS). MELD allocation was introduced in 2002 
based on increasing deaths on the waiting list. The previously defined status I for 
urgent transplant was maintained, but MELD replaced status 2A - C. Concerns have 
been expressed on the increased post-transplant mortality and morbidity when strictly 
following a sickest-first allocation policy, although most studies failed to show greater 
mortality with higher MELD recipients, while undoubtedly morbidity and cost 
significantly increased [49, 50]. The median MELD score at transplant still differs 
greatly based on geography across the US and efforts are underway to resolve this 
issue.  In 2016, allocation according to the MELD-Na was introduced (Tbl. 1-2; supp. 
Tbl. 1-2; Fig. 1–3 and supp. Fig. 1) [51]. In 2019, ECD were accepted and the center-
oriented system refined. 
 
2.2  Canada  
 
Donation policy:   Provincially based 
Prioritization:    MELD-Na 
Priority for HCC:  Yes, extra points granted (22 at listing; 3 points/3 months thereafter) 
Indications for extra points:  Neoplasia, PLD, Cystic fibrosis, FAP, Primary Hyperoxaluria, Metabolic 






The organ allocation system in Canada has been historically based on the 
CanWAIT algorithm, which prioritized patients according to where the patient is 
located (home, hospital ward vs. ICU) and the severity of liver disease [52, 53]. In 
close similarity to the previously utilized allocation systems based on Child-Pugh 
criteria, the CanWAIT algorithm relied heavily upon waiting time to break ties within 
categories. Since the MELD allocation has been shown to be superior to the 
CanWAIT system for predicting waitlist mortality, centres gradually began to adopt 
MELD liver transplant allocation regionally for non-urgent status patients. Starting in 
January 2015, Canada adopted MELD-Na for allocation of liver transplants, although, 
considerable heterogeneity remained in listing criteria regarding MELD 
exceptions. For example, British Columbia and Atlantic Canada use the Milan criteria 
for their patients with HCC. However, they will consider patients with tumors within 
the UCSF criteria, on a case-by-case basis. In Alberta, London and Ontario, total 
tumor volume and αFP are used as selection criteria, although patients can also be 
transplanted within UCSF criteria in the latter two provinces. Due to the regional 
heterogeneity in listing criteria, there is at present a strong focus on advancing 
consensus about allocation criteria for LT within Canada (Tbl. 1-2; supp. Tbl. 1-2; Fig. 
1–3 and supp. Fig. 1) [54]. 
 
3. Latin America (Brazil, Colombia, Argentina and Mexico) 
Argentina:  
Donation policy:   Opt-in 
Prioritization:    MELD 
Priority for HCC:   Yes, extra points granted (22 at listing; additional 1 point/3 months) 







Donation policy:   Opt-in 
Prioritization:    Clinical, MELD, Waiting time 
Priority for HCC:  Yes, extra points granted (20 at listing; 24 points after 3 months, 29 
points after 6 months)   
Indications for extra points:  Neoplasia, PLD, FAP, Metabolic diseases, Recurrent cholangitis,  
HPS, Post-LDLT  
 
Colombia:  
Donation policy:   Opt-out 
Prioritization:    Clinical, MELD, waiting time 
Priority for HCC:   Yes, extra points granted (22 at listing) 
Indications for extra points:  HCC, Age 
 
Mexico:  
Donation policy:   Opt-in 
Prioritization:    Clinical, waiting time 
Priority for HCC:   No 
Indications for extra points:  None 
 
With the recent increase of the number of LT by about 6% per year, Latin 
America has become a very active part of the world [55]. This region has a population 
of 589 million, representing 8.5% of the world population, and more than 2,500 LT 
are performed per year (corresponding to 17% of world activity). The outcome of LT 
in some Latin America countries, such as Brazil (9.2 pmp) and Argentina (9.0 pmp), 
is comparable to those in more developed countries. However, LT is still not 
performed in 35% of Latin American countries, which is mostly due to the lack of 
adequate financial coverage, education as well as organization. MELD–based 





living-donor adult and pediatric transplantations are also routinely performed with 
comparable outcomes to the rest of the world. HCC patients receive standard 
exception points, e.g. Brazilian patients with tumors > 2cm in diameter within the 
Milan criteria, receive 24 points after 3 months on the waiting list. In addition, extra 
points are awarded for a wide variety of conditions such as NET metastases, familial 
amyloid polyneuropathy or hepatopulmonary syndrome (Tbl. 1-2; supp. Tbl. 1-2; Fig. 
1–3 and supp. Fig. 1).   
 
4. Asia-Pacific Region (South Korea, Iran, India, China, Taiwan, 
Australia/New Zealand) 
For details see Tables 1-2 and supp. Tables 1-2 
The countries with the highest living donor rates in the Asian-Pacific region 
have unanimously adopted the allocation systems based on the MELD score for their 
cadaveric organs. Interestingly, at 28.7 per million population, South Korea has 
currently one of the highest donor rates per million inhabitants worldwide. However, 
the deceased organ donation rate remains low. This is due to the fact that the rapid 
development of LT in South Korea has been spurred by the widespread acceptance 
and adoption of living donor liver transplantation (LDLT) [56]. Indeed, since the first 
LT performed in South Korea in 1988, LDLT accounted for approximately 76.5% of all 
liver transplantations in this country [57].  
A large majority of liver transplants performed in India are currently through live 
donation. However, in some states in the Southern & Western regions deceased 
donor liver transplants form a substantial proportion [58]. A national body to regulate 
transplantation called National Organ & Tissue Transplant Organisation (NOTTO) 





models. Both these models recognise a super urgent category. Beyond this, 
allocation is either done by waiting list chronology or by rotational allocation to all the 
recognised liver transplant centres [58]. There is a growing recognition that the model 
needs to change to a severity-based allocation, however, given limited regulatory 
power most states have found this challenging to implement. Data on outcomes of 
liver transplantation in India is currently very inadequate as there is no national 
registry. 
The Asia-pacific region also hosts the Australia & New Zealand Liver Transplant 
Registry. All centers share organs for cases of fulminant hepatic failure. The large 
majority of LT are performed in Australia (281 LT/y). The MELD score is used for 
organ allocation and 22 extra points are awarded for patients with HCC (>2cm and 
within UCSF) with an additional 2 points every 3 months (Tbl. 1-2; supp. Tbl. 1-2; Fig. 






Both the MELD- and center-based allocation systems suffer from inherent 
limitations. A center-specific allocation system fails to provide an objective tool in 
assigning the need for a LT resulting in more deaths on the waiting list, when 
compared to a MELD score-based policy. This shortcoming certainly holds true 
especially in countries, which badly suffer from organ shortage. In view of the recent 
and repetitive scandals in the transplant business, an objectively founded allocation 
process of limited resources appears mandatory [60]. Allocation by recipient’s lab 
MELD score is transparent and objective, but fails taking into account additional 
relevant patient-specific factors, such as factors related to the quality of life (e.g. 
refractory pruritus), the presence of recurrent cholangitis or cancer (Fig. 2; supp. Fig. 
1) [61].   
Limitations of the MELD allocation system are addressed by most players 
including several countries or allocation systems. First, by adding extra-points to the 
recipient’s laboratory MELD score (so-called standard vs. nonstandard exceptions) to 
allow candidates not well served by laboratory changes to compete with higher 
MELD-score recipients [62]. The amount of added points, and its further increase 
during waiting time remains, however, quite subjective and therefore highly 
inconsistent among countries (supp. Tbl. 1). Next, all MELD-based allocation 
systems have been criticized for not defining a threshold for being too sick for 
transplantation [23, 63-65]. To address the issue of futile LT and waste of available 
grafts, i.e. the concept of utility, a variety of additional scores were developed to 
predict poor outcomes. The most accurate scores combine donor and recipient 
factors, such as D-MELD, Delta MELD, survival outcome following LT (SOFT), 





(UCLA-FRS) and survival benefit analysis (Fig. 2; supp. Fig. 1)[19, 64, 66-68].  A 
further development in this direction is the use of artificial neural networks by 
combing approximately 60 donor, graft, and recipient factors to identify best matches 
[28, 69]. Despite all these efforts, however, refusing a liver offer for a very sick 
transplant candidate remained a major challenge and responsibility since outcome 
prediction, not uncommonly, differs among the many available scores and formulas.  
Cancer as an indication for LT requires special attention, as well as the long-
term side effects of immunosuppression in this population. For example, twenty years 
after the introduction of the Milan criteria to select patients with HCC for LT, it is still 
unclear what would be an acceptable aim in recipients transplanted for cancer, some 
have suggested 50% 5-year survival rate [70]. Several other models (e.g. UCSF, up 
to seven, total tumor volume, Kyoto criteria, extended Toronto criteria, MORAL score) 
have been introduced, which typically claim comparable predictive values [30, 71-74] 
(Fig. 3.; Tbl. 2; supp. Tbl. 1-2). Microvascular invasion seems to be the predictive key 
factor, however a reliable and convincing serum or easy available marker is still 
missing [75]. Furthermore, it is unclear how to include other malignancies qualifying 
for LT, such as perihilar or intrahepatic cholangiocarcinoma, or colorectal liver 
metastases [32, 33, 76-79].  
The success of LT over the past 30 years is indisputable and indications are 
likely to widen with the availability of less toxic immunosuppression, leading to an 
ever increasing need for available grafts. Increasing the donor pool relies on living 
donation or the use of marginal organs, such as steatotic livers or livers donated after 
cardiac death (DCD) [18, 80, 81]. Those liver grafts yield a higher risk for failure 
(primary non function) after implantation or developing irreversible biliary injury 





inherent to the DCD procurement [82, 83]. Several countries with DCD experience 
prefer to allocate DCD organs according to a center-specific policy (Tbl. 1.) [42, 84, 
85]. Optimizing techniques such as machine perfusion technology is likely to gain 
wide acceptance to enhance organ quality with an increased availability of grafts for 
transplantation [86, 87]. 
In conclusion, while a perfect liver allocation system is currently not available, 
the sickest first policy represents the most appropriate basis for allocation of liver 
grafts. MELD is currently the standard, however, adjustments have to be 
implemented for diseases poorly served by a liver failure score such as for PSC, 
metabolic disorders or cancer. The BAR score is currently a valuable and easy tool to 
identify high-risk cases for post-transplant mortality and to compare results among 
centers. BAR compared to other scores offers a well-defined cut off for decision 
making. A future globally applicable model should combine donor and recipient 
factors predicting probability of death on the waiting list, post-transplant survival as 
well as morbidity including associated costs. Moreover, a globally applicable model of 
allocation of liver grafts has also to take into account regional ethical, moral, and 
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